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Abstract
Study objectives: Neutrophil influx into the airways is an important mechanism in the pathophysiology of the
inflammatory process in the airways of patients with chronic obstructive pulmonary disease (COPD). Previously it
was shown that anticholinergic drugs reduce the release of non-neuronal paracrine mediators, which modulate
inflammation in the airways. On this basis, we investigated the ability of the long-acting anticholinergic tiotropium
bromide to inhibit a) alveolar macrophage (AM)-mediated chemotaxis of neutrophils, and b) cellular release of
reactive oxygen species (ROS).
Method: AM and neutrophils were collected from 71 COPD patients. Nanomolar concentrations of tiotropium
bromide were tested in AM cultured up to 20 h with LPS (1 μg/ml). AM supernatant was tested for TNFa, IL8, IL6,
LTB4, GM-CSF, MIPa/b and ROS. It was further used in a 96-well chemotaxis chamber to stimulate the migration of
fluorescence labelled neutrophils. Control stimulants consisted of acetylcholine (ACh), carbachol, muscarine or
oxotremorine and in part PMA (phorbol myristate acetate, 0.1 μg/ml). Potential contribution of M1-3-receptors was
ascertained by a) analysis of mRNA transcription by RT-PCR, and b) co-incubation with selective M-receptor
inhibitors.
Results: Supernatant from AM stimulated with LPS induced neutrophilic migration which could be reduced by
tiotropium in a dose dependent manner: 22.1 ± 10.2 (3 nM), 26.5 ± 18,4 (30 nM), and 37.8 ± 24.0 (300 nM, p <
0.001 compared to non-LPS activated AM). Concomitantly TNFa release of stimulated AM dropped by 19.2 ± 7.2%
of control (p = 0.001). Tiotropium bromide did not affect cellular IL8, IL6, LTB4, GM-CSF and MIPa/b release in this
setting. Tiotropium (30 nM) reduced ROS release of LPS stimulated AM by 36.1 ± 15.2% (p = 0.002) and in
carbachol stimulated AM by 46.2 ± 30.2 (p < 0.001). M3R gene expression dominated over M2R and M1R.
Chemotaxis inhibitory effect of tiotropium bromide was mainly driven by M3R inhibition.
Conclusion: Our data confirm that inhibiting muscarinic cholinergic receptors with tiotropium bromide reduces
TNFa mediated chemotactic properties and ROS release of human AM, and thus may contribute to lessen cellular
inflammation.
Introduction
The pathogenesis of chronic obstructive pulmonary dis-
ease (COPD) is characterized by persistent neutrophilic
inflammation of the airways and lung parenchyma [1,2].
They release cytokines, leukotrienes, reactive oxygen
species (ROS), elastases and other proinflammatory
mediators which correlate broadly with disease severity
[3-5]. Neutrophils are attracted from the capillary bed
into the airways through chemotactic mechanisms
which are intensified during exacerbation [6,7]. With
increasing disease severity activated mononuclear cells
and monocytes/macrophages contribute more and more
to the complex inflammatory process in the airways and
in the bronchial submucosa of those patients [8].
Chemotaxis is a biological phenomenon whereby a cell
type migrates through barriers (e.g. vessel walls, epithe-
lial layers or tissue) toward the site of inflammation.
These cells will initiate and maintain the inflammatory
process through a variety of mechanisms including ROS
release. In COPD, chemotaxis is not only regarded as an
important pathologic feature of prolonged inflammation
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due to cigarette smoke inhalation, but may also be an
appealing target for anti-inflammatory therapy. By redu-
cing the neutrophil influx into the airways one should
be able to reduce the burden of airway inflammation
and, thus, change the natural history of the disease
[9,10]. Unfortunately, inhaled corticosteroids have been
shown to reduce neutrophilic inflammation in COPD
patients just poorly at best [11-13]. Long-acting b2-
agonists do not have intrinsic anti-inflammatory proper-
ties per se. In contrast, the long-acting muscarinic
receptor antagonist tiotropium bromide has been shown
a) to regulate release of chemotactic factors from
human epithelial cells and macrophages in vitro [14],
b) to inhibit airway remodelling and increase in smooth
muscle mass in ovalbumin-sensitised guinea pigs
[15,16], and c) to inhibit acetylcholine mediated prolif-
eration of fibroblasts and myofibroblasts in vitro [17,18].
These observations may be based on induced mitogen-
esis by stimulated muscarinic receptors and mediator
release, which can be lessened by muscarinic receptor
antagonists [19].
We hypothesize that tiotropium may have potential
antiinflammatory properties helping to explain its good
clinical efficacy e.g. the reduction of exacerbation rate
which can hardly be related to its bronchodilative func-
tion alone. Through reducing chemotaxis of neutrophils
via inhibition pro-chemotactic properties of alveolar
macrophages anticholinergic drugs and tiotropium in
particular may impact the neutrophil and macrophage
driven inflammation in COPD in a considerable way.
This would be a new perspective how those compounds
affect those patients. The rationale for this study was
therefore to test tiotropium having anti-chemotatic
properties in a macrophage and neutrophil containing
cell system.
Methods
In this study alveolar macrophages and neutrophils from
COPD patients (n = 71) were used. They were recruited
during out-patient or in-patient visits in our institution.
Main inclusion criteria were a smoking history of ≥20
pack-years, COPD regardless of severity according
GOLD -criteria (global initiative for lung disease [20]).
Main exclusion criteria were an acute infection of the
airways or the lung, other chronic lung diseases (except
COPD), cancer or extra-pulmonary chronic diseases
causing clinical instability. All patients gave written,
informed consent. All of them had a clinical history, a
physical examination and an X-ray from the chest prior
to bronchoscopy and bronchoalveolar lavage (BAL).
Appropriate investigations relating to the clinical pre-
sentation together with history including smoking his-
tory, spirometric and radiologic data as well as blood
gas analysis were obtained from the records. The study
was approved by the ethics committee of the Saxonian
Chamber of Physicians, Dresden, Germany (approval
No.: EK-BR-27/05-2).
Patients referred for bronchoscopy for various clinical
reasons were invited to participate in the study. Prior to
bronchoscopy short acting anticholinergic drugs (ipra-
tropium bromide) were stopped for at least 12 h and
the long acting tiotropium bromide for at least 48 h.
Prednisolone was limited to 7,5 mg/day. Inhaled short-
and long-acting b2-agonists, inhaled corticosteroids,
further, antibiotics and theophylline were allowed.
BAL was performed according to standard procedure as
recommended [21,22]. The bronchoscope was wedged in
the right middle lobe or lingula and up to 140 ml of nor-
mal warmed (37°C) saline was instilled in 20-ml aliquots.
Lavage fluid was immediately rinsed through gauze in
order to remove surplus mucus. The fluid was centrifuged
at 800 rpm for 10 minutes, 1 × 106/ml isolated macro-
phages were plated on 24-well tissue culture plates in
RPMI (Biochrom AG)/10%FCS/L-glutamine (2 mM,
GIBCO/Invitrogen)/antibiotics (penicillin 100 IU/ml, strep-
tomycin 100 μg/ml, amphotericin 0,25 mg/ml, Biochrom
AG) and cultured up to 2 h at 37°C/5%CO2. After washing
to remove unattached AM and other cells, cells were
further cultured over night. For estimation of cell viability/
cytotoxicity we used trypan blue and neutral red uptake
assay as described elsewhere [23]. Viability had to be ≥90%,
macrophage content of BAL cell differential ≥85%, and at
least 5 million cells were all required for further analysis.
Cell vitality and cellular purity (microscopic examination of
300 cells at magnification ×100) was always ≥95%. For all
experiments a cellular concentration of 2 × 106 cells/ml
was used. All experiments were run in triplicates.
Polymorphonuclear leukocytes were isolated from the
blood of these patients according to standard procedure
as described elsewhere [24]. They were labelled with
Calcein AM (5 μg/ml, Molecular Probes) in a 30 min
incubation step at 37°C/5% CO2 for later detection
using a flourescence based detection system. Neutrophils
were than washed twice with PBS, counted and resus-
pended in RPMI/FCS/L-glutamine/penicillin/strepto-
mycin/amphotericin [25,26].
AM were washed and incubated at 37°C/5% CO2 for
different time periods with RPMI/1%FCS/L-glutamine/
penicillin/strepto-mycin/amphotericin with or without
increasing concentrations of either acetylcholine (ACh:
1000; 100; 10; 1; 0.1 μM), carbachol, muscarin, oxotre-
morin (100, 10 and 1 μM) or LPS (10, 1 and 0.1 μg/ml;
all reagents from Sigma Chemicals). In addition co-
stimulation was done with LPS (0.1-1 μg/ml) and carba-
chol or muscarin (10-100 μM). After designated time
periods, supernatants were strip off, centrifuged to
remove remaining cells and cell detritus and frozen
(-80°C) for cytokine quantification.
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AM and neutrophils from these patients were pro-
spectively distributed to the different assays. Due to
large assay number and control experiments, as well as
depending on the usefulness of the material and the cell
number obtained from each patient, assays were run
only with a certain proportion of patient samples: n =
20 for chemotaxis with tiotropium, n = 10 for LPS/car-
bachol/muscarin/tiotropium co-stimulation, n = 9 for
controls with acetylcholin-esterase, n = 15 for RT-PCR
experiments, n = 17 for ROS release experiments.
Cytotoxicity
After AM-stimulation with LPS with or without tiotro-
pium (3 nM, 30 nM, 300 nM) for 4 and 20 h, superna-
tants were stripped off. Remaining cells were washed
three times with PBS and cytotoxicity was quantified.
For the estimation of cell cytotoxicity we used neutral
red uptake assay as described elsewhere [23]. Control
cells (cultured with RPMI/1%FCS/antibiotics/glutamine)
were set to 100% and used for normalisation. Proper
staining with 2’,7’-dihydrodichlorofluorescein diacetate
(H2DCFDA) a fluorescent dye used in the cytotoxicity
assay was confirmed by Fluorescence microscopy
(Nikon).
Chemotaxis
Cell migration of neutrophils was assayed using a 96-
well Transwell chamber (pore diameter 3 μm, Corning).
The bottom chamber was filled with culture superna-
tants generated from AM culture supernatant as
described above. Isolated neutrophils (75 μl, 2 × 106
cells) were placed in the upper chamber. Spontaneous
migration during incubation in 37°C/5% CO2 for
60 min. was determined using RPMI alone. RPMI/1%
FCS/L-glutamine/penicillin/strepto-mycin/amphotericin
in the bottom chamber functioned as positive control
(= FCS induced migration). Migrated cells were quanti-
fied in a multi-well fluorescent plate reader (Fluostar,
BMG), whereas the intensity of the calcein fluorescence
signal detected at excitation 485 nm and emission
535 nm in the bottom chamber corresponds to neutro-
phil cells found there. The values of the spontaneous
migration were set to 100% and used for normalisation
of different experiments.
Different muscarinic receptor antagonists were tested to
elucidate the role of specific M-receptors and their inhibi-
tors on chemotactic activity in AM cultured in RPMI/
FCS/L-glutamine/penicillin/streptomycin/amphotericin:
telenzepine (M1R inhibitor, 0.01 μM), gallamine (M2R
inhibitor, 100 μM), 4-DAMP (M3R inhibitor, 100 nM),
tubocurarine (nicotinic receptor inhibitor, 100 μM), ipra-
tropium (30 nM, Sigma Chemicals) and tiotropium (3 nM,
30 nM, 300 nM, provided by Boehringer Ingelheim).
Cytokine measurements
Commercially available ELISA kits were used for the
detection of human IL-8, IL6, TNF alfa, GM-CSF (IBL,
Hamburg, Germany), LTB 4 (Cayman, USA), MIPa/b
(Biosource Int., USA) in AM supernatants with minor
modifications of the manufacturer’s protocol.
Reactive oxygen species (ROS)
Intracellular ROS formation was measured by the oxi-
dant sensitive dye 2’,7’-dichlorofluorescein diacetate
(DCFH-DA [27]). The amount of fluorescence correlates
with ROS released by the cells. AM were cultured under
the above culture conditions (with or without the com-
pounds to be tested), washed in PBS and then incubated
with 1 μl DCFH-DA/1 ml PBS for 1 h at 37°C/5%CO2.
Fluorescence was quantified with FLUOstar OPTIMA
(BMG Labtech). Negative controls consisted of a) AM
cultured without DCFH-DA, and b) AM preincubated
with prednisolone (10 μM). LPS activated AM and PMA
0.1 μg/ml were used as positive controls.
RT-PCR
For quantitative mRNA expression of muscarinic recep-
tors of AM RT-PCR (Rotorgene 3000, Corbett Research)
was used. Total RNA was isolated using Trizol (Invitro-
gen), quantified spectrophotometrically and 1 μg was
reverse transcribed to produce cDNA (Superspcript III
Platinum, Invitrogen). The cDNA was then used to
determine gene expression levels of the muscarinic
receptors M1R-M3 relative to b-actin. The PCR reaction
was performed with primers described by Pieper et al.
[17]. The specificity of PCR reactions was verified by
melting curve analyses and electrophoresis (date not
shown). The primers used had the following sequences:
M1R for (5’-GGCACGCTGGCTTGTGA-3’), M1R rev
(5’-TTCATGACGGAGGCATTGC-3’), M1R-Probe
(FAM-5’-CTGGCCCTGGACTATGTGGCC-3-TAM
RA’), M2R-for (5’- CCTGGAGCACAACAAAATCCA
-3’), M2R-rev (5’- TCCCTGAACACAGTTTTCAGTCA-
3’), M2R-Probe (FAM-5’-ATGGCAAAGCCCCCAGGG
ATCC-3-TAMRA’), M3R-for (5’-ACAGCCCCTCC-
GATGCA -3’), M3R-rev (5’-AACATTGTAGCTGC
CGAAATGA -3’), M3R-Probe (FAM-5’-CTGCCCCCGG
GAACCGTC -3-TAMRA’), b-actin for (5’-TGACGCC
GGCTACAGCTT -3’), b-actin rev (5’-TCCTTAATGT-
CACGCACGATTT -3’), b-actin-Probe (FAM-5’-
ACCACCACGGCCGAGCGG -3-TAMRA’). In order to
exclude that our results were influenced by different
muscarinic receptor expression due to varying culture
conditions, RT-PCR was performed in AM-RNA a)
without over night incubation (2 h after isolation from
BAL), b) with overnight incubation in RPMI/10%FCS/L-
glutamine/penicillin/streptomycin/amphotericin (for
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20 h), c) in control cells (see above), and d) in AM sti-
mulated with LPS (1 μg/ml) or e) carbachol (100 μM).
Statistical analysis
Values were expressed as mean value ± SD (or ± SEM
when indicated) of n experiments. For statistical analysis
to compare the response of AM/neutrophils to tiotro-
pium bromide with and without carbachol acetylcholine,
muscarin and oxotremorin we used the Kruskall-Wallis
test, the Mann-Whitney rank-sum test and the Wilcoxon
signed-rank test respectably, if appropriate. Statistical
significance was accepted at the level of p < 0.05. All sta-
tistical tests were performed using the SigmaStat software
version (SPSS Science).
Results
Patient characteristics are shown in table 1.
Chemotaxis
Supernatant from AM stimulated with LPS (0.1, 1 and
10 μg/ml) caused a concentration-dependent increase in
the neutrophilic migration. A LPS concentration of
1 μg/ml resulted in an optimal chemotaxis, and was
used in all consecutive experiments.
Involvement of muscarinic receptors in LPS-mediated
effects
Supernatant from AM cultured with LPS and the
anticholinergic drug tiotropium (30 nM) resulted in a
significant (p < 0.001) reduction of neutrophil migra-
tion compared with supernatant from AM cultured
with LPS alone (figure 1). Tiotropium had no effect on
migration rates in the absence of LPS (data not
shown). Taken together, these data suggest that
activation of muscarinic receptors was involved in the
LPS-mediated release of chemotactic factors. To
further investigate this point, co-incubation experi-
ments with AChE (acetylcholinesterase) added to LPS
stimulated AM cell medium (n = 9) resulted in
reduced migration rates of neutrophils: 154% ± 33% of
control (LPS alone), 113% ± 17% (LPS+AChE, p value
< 0.001), suggesting that acetylcholine release and con-
sequent activation of muscarinic receptors are part of
the signalling cascade activated by LPS.
To further explore this aspect, AM were stimulated
with different muscarinic agonists, i.e. acetylcholine, car-
bachol, muscarin and oxotremorine. However, neither of
these agonists induced neutrophilic migration alone, nor
potentiated LPS-mediated effect [+45.5 ± 39.1% (LPS+
acetylcholine), +12.3 ± 12.7% (LPS+carbachol), +15.2 ±
19.8% (LPS+muscarin), +21.2 ± 17.1% (LPS+oxotremor-
ine), +41.5 ± 23.2% (LPS)]. Taken together, these data
suggest that ACH release and muscarinic receptor acti-
vation are a necessary component in LPS mediated
effect, but not sufficient.
Detection of which muscarinic receptor subtype is
involved in LPS effects
The analysis of muscarinic M1R, M2R and M3R
mRNAs by RT-PCR showed that all the subtypes are
present in AM, with muscarinic M3R mRNA transcripts
dominating over M2R, and M1R (figure 2). 20 h after
isolation from BAL, M-receptor expression increased
compared with 2 h incubation (p < 0.001). At the 20 h
time point M-receptor expressions did not vary regard-
less of stimulants added to the cell medium (figure 3).
The muscarinic M3R antagonist 4-diphenylacetoxy-N-
methylpiperidine methiodide (4-DAMP) and tiotropium
Table 1 Baseline parameters of patients (mean ± SD)
Parameter Value
N 71
Women n = 46 (64.8%)
Men n = 25 (35.2%)
Lung function and blood gas analysis
FEV1 (%predicted) 80.3 ± 23.1
FEV/FVC (%) 69.1 ± 7.6
pO2 (mmHg) 72.5 ± 12.1
pCO2 (mmHG) 37.0 ± 3.4
pH 7.4 ± 0.01
Cell differential of bronchoalveolar lavage
Alveolar macrophage [%] 91.1 ± 7,2
Neutrophils [%] 5.2 ± 3,1
Lymphocyte [%] 1.9 ± 0,7
Eosinophils [%] 0.7 ± 0,4
Mast cells [%] 0.1 ± 0,3
Total cells [106] 8.9 ± 5,5
Figure 1 Tiotropium inhibited chemotactic activity from LPS
activated AM (test runs from left to right: n = 4, n = 9, n = 20
patients). Mean ± SD (standard deviation). * p < 0.001 compared
with LPS activation without inhibition. Concentrations according to
expected values in the airways after tiotropium inhalation
http://www.rxlist.com/cgi/generic3/spiriva_cp.htm.
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(p < 0.01 vs. LPS stimulation alone) reduced neutrophi-
lic migration rate in our chemotaxis system, whereas the
muscarinic M1R-receptor antagonist pirenzepine and
M2R antagonist gallamine did not (figure 4).
Taken together, these data suggest that, in this model,
ACh exerts its activity through the activation of the
human M3R, which is also the most expressed subtype
in AM.
Anticholinergic effects in reducing mediator release
As expected, LPS exposure of AM resulted in an
increase of many pro inflammatory mediators, as TNF-
a, IL-8, IL-6, LTB4, GM-CSF and MIPa/b (data not
shown). Coincubation with tiotropium (30 nM) resulted
in a significant reduction of elevated TNFa secretion
from LPS stimulated AM, which correlated fairly with
the reduction of neutrophil migration rates (R2=0.335,
p < 0.001, figure 5). Concerning the other cytokines, tio-
tropium had no significant effect (date not shown).
Release of reactive oxygen species in AM
ROS are another important pro-inflammatory stimulus
in COPD which is known to be a chemotactic factor.
We therefore tested tiotropium bromide also to reduce
ROS in order to further elucidate anti-inflammatory effi-
cacy of this compound. Among the different stimuli
tested, PMA (0.1 μg/ml) generated the highest ROS
release in cultured AM, followed by LPS, which in turn
is a stronger stimulus than carbachol. As expected, dex-
ametasone (10 μM), which was used as positive control,
substantially reduced LPS mediated ROS (figure 6). In
11 out of 16 patients tiotropium (30 nM) reduced ROS
production from LPS stimulated AM by 36.1%. After
Figure 2 Cellular mRNA levels of muscarinic M1R (MRC1), M2R
(MRC2), M3R (MRC3) subreceptors in alveolar macrophages
from COPD patients (n = 11). Mean+SD.
Figure 3 Differences in muscarinic receptor (MRC1-3)
expression profile in AM from n = 19 COPD patients
depending on culture conditions. X-axis represents comparisons
always after an incubation time of 20 h: carbachol vs. control, LPS
vs. control, 20 h vs. 2 h, LPS+ACh vs. LPS. Mean ± SD. * p = < 0.001
(repeated measures One Way ANOVA).
Figure 4 Inhibition of AM induced chemotactic activity from
tiotropium on neutrophils is predominantly driven by M3R-
blockage (n = 10): Tiotropium 30 nM, 4-DAMP 100 nM (each: p
< 0.01 vs. LPS stimulation alone), Ipratropium 30 nM,
Gallamine 100 μM, Tubocurarine 100 μM, Telenzepine 10 nM.
Doses were adapted from earlier studies and customized to our
assay conditions [43,63,64].
Figure 5 Correlation of TNFa release of pre-cultured and LPS
activated alveolar macrophages (AM) to the migration rate of
neutrophils cultured with AM cell medium (Tiotropium 30 nM).
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stimulation with carbachol (100 μM), tiotropium
induced a 46.2% reduction in ROS release; (p < 0.001 vs.
LPS or carbachol alone; figure 7).
Discussion
Clinical studies in COPD patients using inhaled anticho-
linergic tiotropium 18 μg once daily revealed reduced
exacerbation rates as well as an improvement of lung
function and the natural course of COPD [28,29]. The
underlying mechanism how long-term treatment with
tiotropium prevents exacerbations in these patients is
unclear since the drug is regarded as a bronchodilator
apparently lacking antiinflammatory capabilities in vivo
[30,31]. COPD exacerbations are at the cellular level
characterized by increasing systemic and bronchial
inflammation which can be at least in part influenced by
long-term treatment of inhaled corticosteroids [32-36].
It is unlikely that pure bronchodilation may cause this
phenomenon because long-acting b2-agonist therapy
alone is unable to reduce exacerbation rates and exacer-
bation severity to a clinically meaningful extent [37-39].
COPD has a high driving force to recruit inflamma-
tory cells from the capillary bed into the airways [40]
which is at least in part regulated by the muscarinic
cholinergic system [41,42]. The ACh promoting effect
on neutrophilic migration rate is dose dependent as
Sato et al were able to demonstrate in ACh (1-100 μM)
activated bovine alveolar macrophages [43]. In concor-
dance with other studies, our data demonstrate a) that
ACh drives chemotaxis since AChE reduces LPS-
induced neutrophilc migration rates by about 40%, and
b) that long-acting muscarinic receptor antagonist tio-
tropium bromide has additional anti-inflammatory cap-
abilities due to reducing chemotactic activity of cultured
AM in vitro. In regard to chemotaxis induction, ACh
proved to be a much weaker driving force than LPS,
suggesting that its role in LPS-mediated effects is neces-
sary, but not sufficient to induce migration. Also, exo-
genously added ACh did not further enhance LPS
efficacy, suggesting that LPS is per se already very effica-
cious and maximal chemotaxis was already reached
(ceiling effect). Because of that, we run our experiments
solely with LPS. In our experimental setup tiotropium
bromide reduced LPS-mediated chemotaxis, possibly
through an antiinflammatory effect as indicated by the
reduction of TNFa release. Anti-inflammatory drugs,
such as phosphodiesterase 4 inhibitors, have been
shown to reduce TNFa and chemotaxis in sputum of
COPD patients [44] which is at least in part mediated
by mitogen activated protein (MAP) kinase pathway
[45]. Our data may point to a similar effect of tiotro-
pium bromide. However, TNFa reduction correlated
weakly with the drop of chemotaxis, hinting that other
mechanisms may be involved in tiotropium bromide
influence in human alveolar macrophage/neutrophil
chemotaxis. Because the supernatant used in the chemo-
taxis chamber contained tiotropium it might have
exerted an additional effect on neutrophils which also
express muscarinic receptors [14].
Surprisingly, tiotropium bromide failed to have any
impact on the chemotactic mediators IL8, IL6, LTB4
and GM-CSF but not on cellular ROS release. Various
other studies in myocytes also emphasize the stimulating
effect of ACh on ROS production which is caused by
activation of PI3K, Src-kinases or the ERK pathway at
last leading to opening of mitochondrial KATP channels
and ROS release [46,47]. ROS by themselves trigger che-
mokine production in inflammatory cells thus enhancing
the inflammatory process [48,49]. The involvement of
the cholinergic system in ROS and ROS-mediated cyto-
toxicity make it an ideal system to test muscarinic
receptor inhibitors for their cell protective function.
In this context we were able to demonstrate that
Figure 6 ROS (reactive oxygen species) release from LPS,
PMA or carbachol activated alveolar macrophages (AM) from
16 patients. ROS production in unstimulated cells was defined as
100%, ROS in cell free medium was 0. LPS 1 μg/ml; Carb =
carbachol in various concentrations; Dexam = Dexametasone 10-7 M
in LPS activated AM; PMA 0.1 μg/ml. Data expressed as mean ± SD.
*p < 0.001 vs. LPS.
Figure 7 Inhibition of ROS release by tiotropium (3 × 109 M) in
LPS (1 μg/ml) or carbachol (10-4 M) activated alveolar
macrophages. *p < 0.001, both comparisons with LPS or carbachol
alone. Mean ± SD.
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nanomolar concentrations of tiotropium protect cells by
reducing the oxidant load produced by alveolar macro-
phages and LPS-mediated cytotoxicity. The concentra-
tion needed to obtain the cell protective effect in our
cytotoxicity assay is in a physiologic range which can be
achieved in human airways after inhalation. However,
best protection was seen at high concentrations
(300 nmolar). Possibly, reduction of ROS release is
another mechanism by which tiotropium bromide limits
chemotaxis. Our data are in good concordance with
Wollin and Pieper describing a dose-dependent reduc-
tion of pulmonary neutrophilic inflammation of inhaled
tiotropium (0.01 - 0.3 mg/ml) in smoke exposed mice
[50], but they seem to defy Perng et al. [31], who didn’t
detect any antiinflammatory effect of tiotropium in
humans. The difference between the three studies may
be due to the lack of a placebo arm in the COPD trial
in which all 3 treatment arms (fluticasone/sameterol,
fluticasone/tiotropium, tiotropium alone) failed to show
differences in the cellular component in sputum
although differences in some inflammatory mediators
were observed.
Profita et al. (2008) demonstrated in 16HBE cells that
acetylcholine-mediated IL-8 release significantly
increased chemotaxis of neutrophils. This effect was
inhibited by tiotropium bromide [51]. In the A549 and
MonoMac6 cell line as well as in alveolar macrophages
derived from non-smoking patients without a pulmonary
disease tiotropium bromide decreased the release of che-
motactic mediators after stimulation with high doses of
ACh (100 μM) by about 70% [14]. Because ACh did not
influence cellular release of IL-8 and monocyte chemo-
tactic protein-1 (MCP-1) the authors suggested that leu-
kotriene B4 (LTB4) was the driving force of chemotactic
activity.
However, the authors failed to clearly demonstrate
that the reducing effects of tiotropium bromide correlate
with inhibition of cellular LTB4 release. Nevertheless
there is clear relationship between ACh mediated LTB4
release and chemotaxis of inflammatory cells in COPD
patients, who have higher LTB4 amounts in induced
sputum, which correlates with number of sputum neu-
trophils, than healthy volunteers. ACh (100 μM) stimu-
lated sputum cells from COPD patients but not from
non-smokers release LTB4. Also in blood monocytes
LTB4-production was ACh sensitive. These effects could
be blocked by an inhibitor of extra cellular signal-regu-
lated kinase, but also by the anticholinergic compound
oxitropium bromide at a concentration of 10 μM [52].
However, this drug concentration is high when taking
into account that by inhalation only nanomolar concen-
trations can be achieved locally http://www.rxlist.com/
cgi/generic3/spiriva_cp.htm. The reason why we failed
to demonstrate an inhibitory effect of tiotropium
bromide on IL8 or LTB4 release from AM may be
dependent on the chosen cells, since we evaluated
human AM and human neutrophils instead of using a
cell line. Because of working with primary cells, we
think that our model is more representative of the situa-
tion in the airways of COPD patients.
It seems reasonable that M-receptor blockage inhibits
chemotaxis, reduces anti-proliferative effects and ROS
release, since activation of the cholinergic system has
been shown a) to induce proliferative processes in air-
way tissue in vitro [53] as well as in vivo [16,19],
b) to induce eosinophilic chemotactic activity [43,54],
and c) ACh potentates the release of pro-inflammatory
15-HETE and prostaglandin E2 [55]. Further, cell prolif-
eration of fibroblasts and myofibroblasts could be
blocked by the nicotinic antagonist n-tubocurarine and
antimuscarinic compounds [17,53], and progression of
airway smooth muscle remodeling in a allergen chal-
lenge asthma model could be minimized using tiotro-
pium bromide [16].
M1R, M2R and M3R mRNAs were all present in
AM. M3R mRNA transcripts dominate over M2R, and
M1R and expression increased 20 h compared with the
beginning. We could confirm previous studies also
showing muscarinic receptor expression in cell cul-
tures. Differences in the extent of mRNA transcript
levels are most likely related to different cell types [51]
or different experimental set up and patient character-
istics [52].
Our study has some shortcomings. First, although 71
patients were recruited, the number of single measure-
ments of each assay block was low, which was due to
the numerous controls and limited cell number per
patient. However, due to strict selection criteria, data
from the different experimental settings still are com-
parable. Second, due to numerous controls, number of
single measurements seems low, and would have
otherwise resulted in better statistics. This relates in
particular to the weak TNFa/chemotaxis correlation.
Third, in only about 50% of the cytotoxicity and ROS
experiments in which the various inhibitors were
tested, tiotropium bromide revealed inhibitory efficacy.
This observation is not unique for our work since it
has been found also in other studies on this subject.
Blaas et al stimulated primary epithelial lung cells
with carbachol (100 μg/ml) and found only in 5 out of
12 patients enhanced IL-8 release. In their experi-
ments neutrophilic migration could be induced by car-
bachol in about 40% of their patients [56]. Subject
variability [57,58], health status, varying nicotine con-
sumption [59], cell type [60] and species differences
[61,62] may be confounding factors contributing to
this phenomenon. Forth, the number of migrated cells
in our chemotaxis chamber system seems low in
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comparison to other publications. To detect more
objectively migrated neutrophils and in order to
enable high output measurements we used a fairly
new chemotaxis chamber detecting fluorescence as
the cellular marker for leukocyte migration. Other
papers simply count the cells by light microscopy in
the adjacent chamber as well as the filter whereas our
system only detects truly migrated cells disregarding
those cells sticking in the filter. Our assay has been
described to comprise significant advances quantifying
leukocyte chemotaxis and explains the differences to
previous publications [26].
Conclusion
Our results show that tiotropium bromide inhibits AM
mediated chemotaxis of neutrophils. This effect corre-
lates at least in part by concomitant TNFa reduction.
Further, it reduces cellular proinflammatory activities
such as the generation of ROS. Experiments with selec-
tive M -receptor inhibitors indicate that the M3R sub-
type is responsible for tiotropium bromide inhibition of
chemotaxis.
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